Canada’s contract to work with a Chinese drug company on its COVID-19 vaccine included an arbitration process for resolving disputes, but as the deal fell apart last year, the National Research Council never used the provision.

Canada’s contract to work with a Chinese drug company on its COVID-19 vaccine included an arbitration process for resolving disputes, but as the deal fell apart last year, the National Research Council never used the provision.
